• In addition to being used to treat more than 80 serious anomalies today, in both adults and children, medical research is constantly developing new stem cell therapies from umbilical cord blood.
  

• They can become different cell lines in addition to hematopoietic ones and proliferate very easily.
  

• The stored cells have a 100% genetic compatibility with the baby. And not only with the baby, but also with close relatives, for example the possibility of compatibility with them is of at least 25%
  

• These cells are virgin; Previously they have not been subjected to any invasive agent
  

• The availability in case of need is immediate, avoiding the waiting time that would mean the search for a compatible donor and subsequent checks.
  

• There is no ethical problem arising from its collection, processing, storage and use in medical applications.

• The cord blood is collected by a simple, safe and painless procedure, without affecting the health of the baby nor the mother. Nor to the normal development of the childbirth.

At present, and thanks to the advances of medical science, stem cells can be used to treat more than 80 serious anomalies in both adults and children. Among them we find certain tumors and diseases of the blood:

• Anemia: Deficiencies or malformations of the red blood cells (all therapies are allogeneic)
• Hereditary platelet abnormalities: Platelets are blood cells needed for clotting
• Bone marrow cancers
• Leukemias: Leukemia is a cancer of the immune system of the blood, whose cells are called leukocytes or white blood cells
• Lymphomas: cancer of the leukocytes circulating in the blood and lymphatic vessels
• Myelodysplastic syndromes: Myelodysplasia also called pre-leukemia
• Hereditary Immune System Disorders   
• Myeloproliferative disorders   
• Phagocyte disorders: Phagocytes are cells of the immune system that can wrap and kill foreign organisms   
• Hereditary Red Blood Cell Disorders: Red blood cells are hemoglobin-containing blood cells and distribute oxygen to the rest of the body's cells and tissues   
• Hereditary disorders affecting the immune system and other organs
• Congenital metabolic disorders
• Others.

Bibliography on current treatments with umbilical cord blood stem cells and / or umbilical cord tissue in:
ZB MED Search Portal for Life Sciences
(Www.http: //www.zbmed.de/en/site-search)
More information on clinical trials with stem cells:
Www.clinicaltrials.gov (search for "stem cells" "umbilical cord blood stem cells")

• Alzheimer's
• Arthritis
• Autism   
• Breast cancer   
• Renal cell carcinoma  
• Hepatic cirrhosis  
• Ulcerative colitis   
• Type I Diabetes   
• Type II Diabetes  
• Bronchopulmonary dysplasia  
• Duchenne dystrophy  
• Cartilage and bone disease  
• Acute and Chronic Coronary Disease   
• Eye Diseases
• Peripheral veno-occlusive disease   
• Epidermolysis Bullosa   
• Amyotrophic Lateral Sclerosis   
• Multiple sclerosis   
• Systemic sclerosis
• Cystic fibrosis
• Urinary incontinence
• Cerebral stroke
• Spinal Cord Injury   
• Cerebral palsy   
• Hearing loss

   

  The Spanish Society of Hematology and Hemotherapy reports that umbilical cord blood from Spanish donors has allowed, to date, to save the lives of 1,934 patients who needed a blood stem cell transplant.
  (* Www.sehh.es / images / stories / resources / 2013 / news / NOTICIA1.pdf)
  Criterion of the Spanish Society of Hematology and Hemotherapy on the autologous use of umbilical cord blood: "Today the probability that an autologous cord blood unit is used for transplantation is very low and its use has been limited to pathologies in Pediatrics, mainly in acquired medullary aplasia, high-risk solid tumors (neuroblastomas, Ewing's sarcoma, medulloblastoma and germinal tumors) and some non-Hodgkin's lymphomas in the second remission. There is currently no clear evidence that these cells can be used for Regenerative medicine or to treat other diseases in the future. There are several initial clinical trials to test autologous cell efficacy for some indications. However, it is currently impossible to predict research results that may affect the potential future use of these cells "